Founded in 2005, Porton Pharma Solutions Ltd.is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for small molecule, Large molecule and Gene and Cell Therapies from pre-clinical to commercialization. With more than 5000 skilled employees working across more than 20 sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines.Porton is publicly listed on the Shenzhen Stock Exchange (Ticker: 300363).